FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385334175> ?p ?o ?g. }

• W4385334175 endingPage "904" @default.
• W4385334175 startingPage "899" @default.
• W4385334175 abstract "Background: Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated lopinavir/ritonavir given twice-daily produces suboptimal lopinavir concentrations in young children. We evaluated whether increased daily dosing with modified 8-hourly lopinavir/ritonavir 4:1 would maintain therapeutic plasma concentrations of lopinavir in children living with HIV receiving rifampicin-based antituberculosis treatment. Methods: Children with HIV/tuberculosis coinfection weighing 3.0 to 19.9 kg, on rifampicin-based antituberculosis treatment were commenced or switched to 8-hourly liquid lopinavir/ritonavir 4:1 with increased daily dosing using weight-band dosing approach. A standard twice-daily dosing of lopinavir/ritonavir was resumed 2 weeks after completing antituberculosis treatment. Plasma sampling was conducted during and 4 weeks after completing antituberculosis treatment. Results: Of 20 children enrolled; 15, 1–7 years old, had pharmacokinetics sampling available for analysis. Lopinavir concentrations (median [range]) on 8-hourly lopinavir/ritonavir co-administered with rifampicin (n = 15; area under the curve 0–24 55.32 mg/h/L [0.30–398.7 mg/h/L]; C max 3.04 mg/L [0.03–18.6 mg/L]; C 8hr 0.90 mg/L [0.01–13.7 mg/L]) were lower than on standard dosing without rifampicin (n = 12; area under the curve 24 121.63 mg/h/L [2.56–487.3 mg/h/L]; C max 9.45 mg/L [0.39–26.4 mg/L]; C 12hr 3.03 mg/L [0.01–17.7 mg/L]). During and after rifampicin cotreatment, only 7 of 15 (44.7%) and 8 of 12 (66.7%) children, respectively, achieved targeted pre-dose lopinavir concentrations ≥1mg/L. Conclusions: Modified 8-hourly dosing of lopinavir/ritonavir failed to achieve adequate lopinavir concentrations with concurrent antituberculosis treatment. The subtherapeutic lopinavir exposures on standard dosing after antituberculosis treatment are of concern and requires further evaluation." @default.
• W4385334175 created "2023-07-29" @default.
• W4385334175 creator A5002555774 @default.
• W4385334175 creator A5004112513 @default.
• W4385334175 creator A5012642427 @default.
• W4385334175 creator A5014029759 @default.
• W4385334175 creator A5015306937 @default.
• W4385334175 creator A5019863744 @default.
• W4385334175 creator A5021381528 @default.
• W4385334175 creator A5025069184 @default.
• W4385334175 creator A5026732173 @default.
• W4385334175 creator A5030902925 @default.
• W4385334175 creator A5036808309 @default.
• W4385334175 creator A5052674918 @default.
• W4385334175 creator A5064382030 @default.
• W4385334175 creator A5066890601 @default.
• W4385334175 creator A5092558327 @default.
• W4385334175 date "2023-07-20" @default.
• W4385334175 modified "2023-10-13" @default.
• W4385334175 title "Inadequate Lopinavir Concentrations With Modified 8-hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV" @default.
• W4385334175 cites W1483464410 @default.
• W4385334175 cites W1992857384 @default.
• W4385334175 cites W2036389186 @default.
• W4385334175 cites W2039734639 @default.
• W4385334175 cites W2039770313 @default.
• W4385334175 cites W2049667432 @default.
• W4385334175 cites W2106046029 @default.
• W4385334175 cites W2145319476 @default.
• W4385334175 cites W2344624438 @default.
• W4385334175 cites W2470303801 @default.
• W4385334175 cites W2601854508 @default.
• W4385334175 cites W2775699062 @default.
• W4385334175 cites W2801330756 @default.
• W4385334175 cites W2892487298 @default.
• W4385334175 cites W2945979719 @default.
• W4385334175 cites W3004876156 @default.
• W4385334175 cites W3122800558 @default.
• W4385334175 cites W4286252829 @default.
• W4385334175 doi "https://doi.org/10.1097/inf.0000000000004047" @default.
• W4385334175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37506295" @default.
• W4385334175 hasPublicationYear "2023" @default.
• W4385334175 type Work @default.
• W4385334175 citedByCount "0" @default.
• W4385334175 crossrefType "journal-article" @default.
• W4385334175 hasAuthorship W4385334175A5002555774 @default.
• W4385334175 hasAuthorship W4385334175A5004112513 @default.
• W4385334175 hasAuthorship W4385334175A5012642427 @default.
• W4385334175 hasAuthorship W4385334175A5014029759 @default.
• W4385334175 hasAuthorship W4385334175A5015306937 @default.
• W4385334175 hasAuthorship W4385334175A5019863744 @default.
• W4385334175 hasAuthorship W4385334175A5021381528 @default.
• W4385334175 hasAuthorship W4385334175A5025069184 @default.
• W4385334175 hasAuthorship W4385334175A5026732173 @default.
• W4385334175 hasAuthorship W4385334175A5030902925 @default.
• W4385334175 hasAuthorship W4385334175A5036808309 @default.
• W4385334175 hasAuthorship W4385334175A5052674918 @default.
• W4385334175 hasAuthorship W4385334175A5064382030 @default.
• W4385334175 hasAuthorship W4385334175A5066890601 @default.
• W4385334175 hasAuthorship W4385334175A5092558327 @default.
• W4385334175 hasBestOaLocation W43853341751 @default.
• W4385334175 hasConcept C112705442 @default.
• W4385334175 hasConcept C126322002 @default.
• W4385334175 hasConcept C142462285 @default.
• W4385334175 hasConcept C142724271 @default.
• W4385334175 hasConcept C159047783 @default.
• W4385334175 hasConcept C2777182164 @default.
• W4385334175 hasConcept C2777288759 @default.
• W4385334175 hasConcept C2778607973 @default.
• W4385334175 hasConcept C2779298103 @default.
• W4385334175 hasConcept C2781069245 @default.
• W4385334175 hasConcept C2781392899 @default.
• W4385334175 hasConcept C2993143319 @default.
• W4385334175 hasConcept C3013748606 @default.
• W4385334175 hasConcept C71924100 @default.
• W4385334175 hasConcept C90924648 @default.
• W4385334175 hasConcept C98274493 @default.
• W4385334175 hasConceptScore W4385334175C112705442 @default.
• W4385334175 hasConceptScore W4385334175C126322002 @default.
• W4385334175 hasConceptScore W4385334175C142462285 @default.
• W4385334175 hasConceptScore W4385334175C142724271 @default.
• W4385334175 hasConceptScore W4385334175C159047783 @default.
• W4385334175 hasConceptScore W4385334175C2777182164 @default.
• W4385334175 hasConceptScore W4385334175C2777288759 @default.
• W4385334175 hasConceptScore W4385334175C2778607973 @default.
• W4385334175 hasConceptScore W4385334175C2779298103 @default.
• W4385334175 hasConceptScore W4385334175C2781069245 @default.
• W4385334175 hasConceptScore W4385334175C2781392899 @default.
• W4385334175 hasConceptScore W4385334175C2993143319 @default.
• W4385334175 hasConceptScore W4385334175C3013748606 @default.
• W4385334175 hasConceptScore W4385334175C71924100 @default.
• W4385334175 hasConceptScore W4385334175C90924648 @default.
• W4385334175 hasConceptScore W4385334175C98274493 @default.
• W4385334175 hasIssue "10" @default.
• W4385334175 hasLocation W43853341751 @default.
• W4385334175 hasLocation W43853341752 @default.
• W4385334175 hasLocation W43853341753 @default.
• W4385334175 hasOpenAccess W4385334175 @default.
• W4385334175 hasPrimaryLocation W43853341751 @default.

• next